Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Amir Goldkorn, Catherine Tangen, Melissa Plets, Daniel Bsteh, Tong Xu, Jacek K. Pinski, Sue Ingles, Timothy Junius Triche, Gary R. MacVicar, Daniel A. Vaena, Anthony W. Crispino, David James McConkey, Primo N Lara, Maha H. A. Hussain, David I. Quinn, Tanya B. Dorff, Ian Thompson, Neeraj Agarwal
Institutions: University of Southern California, USC Norris Comprehensive Cancer Center, Fred Hutch Cancer Center, Children's Hospital of Los Angeles, Illinois CancerCare, University of Iowa Hospitals and Clinics, University of Iowa Holden Comprehensive Cancer Center, Johns Hopkins Hospital, UC Davis Comprehensive Cancer Center, Northwestern University, City Of Hope National Medical Center, Christus Health, University of Utah, Huntsman Cancer Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4379281561